Filing would offer added protection to IP already submitted to USPTO VANCOUVER, BC, June 22, 2022 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has…

Source

Previous articleIncannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea
Next articleField Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2022 Results Conference Call for Thursday, June 30, 2022 at 8:30 AM ET